Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
about
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
P2860
Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@ast
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@en
type
label
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@ast
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@en
prefLabel
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@ast
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@en
P2093
P2860
P356
P1476
Similar efficacy and tolerabil ...... is of the German 'WIP' cohort.
@en
P2093
D Schleehauf
P2860
P304
P356
10.1177/0956462416679550
P577
2016-01-01T00:00:00Z